Invasive aspergillosis in hematological and cancer patients

1. Denning D., Kibbler C., Barnes R.A. British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. Lancet 2003; 3: 230–40.

2. Stevens D.A., Kan V.L., Judson M.A. et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000; 30: 676–709.

3. Масчан А.А. Клиника, диагностика и лечение инвазивного аспергиллеза у детей с онкогематологическими заболеваниями. Пособие для врачей. М., 2005.

4. Kibbler C.C., Mackenzie D.W.R., Odds F. C. Principles and practice of clinical mycology. Chichester, N Y, John Wiley & Sons; 1996.

5. Anaissie E.J., McGinnis M.R., Pfaller M.A. (eds.) Clinical Mycology. Churchill Livingstone, 2003.

6. Leenders A.C., van Belkum A., Behrendt M. et al. Density and molecular epidemiology of aspergillus in air and relationship outbreaks of aspergillus infection. Clin Microbiol 1999;37(6):1752–7.

7. Warris A., Verweij P.E. Clinical implications of environmental sources for Aspergillus. Med Micol 2005; 43 (Suppl 1): S59–65.

8. Петрова Н.А., Клясова Г.А. Возможные источники аспергиллезной инфекции в гематологической больнице. Тер арх 2005;77(7):71–7.

9. Oren I., Haddad N., Finkelstein R., Rowe J.M. Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters. Am J Hematol 2001;66(4):257–62.

10. Prentice H.G., Kibbler C.C., Prentice A.G. Toward a targeted, risk based antifungal strategy in neutropenic patients. Br J Haematol 2000: 110; 273–84.

11. Steinbach W.J., Stevens D.A. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis 2003; 37 (Suppl 3): S157–87.

12. Cordonnier C., Ribaud P., Herbrecht R. et al. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. Clin Infect Dis 2006; 42: 966–3.

13. Marr K.A., Boeckh M., Carter R.A. et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39: 797–802.

14. Dimopoulos G., Piagnerelli M., Berre J. et al. Disseminated aspergillosis in intensive care patients: an autopsy study. J. Chemother. 2003; 15: 71–5.

15. Meersseman W., Vandecasteele S.J., Wilmer A. et al. Invasive aspergillosis in critically ill patients without malignancy. Am J Resp Crit Care Med 2004; 170: 621–5.

16. Lutz B.D., Jin J., Rinaldi M.G. et al. Outbreak of invasive Aspergillus infection in surgical patients, associated with a contaminated air-handling system. Clin Infect Dis 2003;37(6):786–93.

17. Schwartz S., Ruhnke M., Ribaud P. et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005; 106: 2641–5.

18. Catalano L., Picardi M., Anzivino D. et al. Small bowel infarction by Aspergillus. Haematologia 1997; 82:182–3.

19. Maertens J., Thenissen K., Verhoef G. et al. Galactomannan and computed tomography based preemptive antifungal therapy in neutropenic patients at highrisk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41: 2733–41.

20. Самохвалова М.В. Возможности компьютерной томографии в дифференциальной диагностике микотических поражений легких. Автореф. дис. … канд. мед. наук. С.-Пб., 2005.

21. Pfeiffer C., Fine J., Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay:a meta-analysis. Clin Infect Dis 2006; 42: 1417–27.

22. Yeo S.F., Wong B. Current status of nonculture methods for diagnosis of invasive fungal infections. Clin Microbiol Rev 2002; 15: 465–84.

23. Perfect J.R., Cox G.M., Lee J.Y. et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of Aspergillosis. Clin Infect Dis 2001;33:1824–33.

24. Herbrecht R., Denning D.W., Patterson T.F. et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408–15.

25. Pearson M.M., Rogers D., Cleary J.D., Chapman S.W. Voriconazole: a new triazole antifungal agent. Ann Pharmacother 2003; 37:420–32.

26. Johnson M.D., MacDougall C., Ostrosky-Zeichner L. et al. Combination antifunfal therapy. Antimicrob Agents Chemother 2004; 48: 693–715.

27. Kantoyiannis D.P., Hachem R., Lewis R.E. et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematological malignancies. Cancer 2003; 98: 292–9.

28. Letscher-Bru V., Herbrecht R. Caspofungin: the first representative of a new antifungal class. J Antimicrob Chemother 2003; 51:513–21.

29. Maertens J., Raad I., Petrikkos G. et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory or intolerant to conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563–71.

30. Aliff T.B., Maslak P.G., Jurcic J.G. et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin B. Cancer 2003; 97: 1025–32.

31. Maertens J., Glassmacher A., Herbrecht R. et al. Multicenter, noncomparative study of caspofungin combined with other antifungals in adults with invasive aspergillosis refractory or intolerant to prior therapy: final data. 45th ICAAC, 2005.

32. Segal B.H., Kwon-Chung J., Walsh T.J. et al. Immunotherapy for fungal infections. Clin Infect Dis 2006; 42: 507–15.

33. Perfect J.R., Marr K., Walsh T. Voriconazole treatment for less common, emerging or refractory fungal infection. Clin Infect Dis 2003;36 1122–31.

34. Wingard J.R. Empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 2004; 39: S38–43.

35. Hughes W.T., Armstrong D., Bodey G.P. et al. 2002 Guidelines for the use of the antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730–51.

36. Walsh T., Teppler H., Donowitz G.H. et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Eng J Med, 2004; 351: 1391–402.

37. Castagnola E., Machetti M., Bucci B., Viscoli C. Antifungal prophilaxis with azole derivates. Clin Microbiol Infect 2004; (Suppl. 10): S86–95.

38. Аравийский Р.А., Климко Н.Н., Васильева Н.В. Диагностика микозов. С.-Пб., Издательский дом СПб МАПО; 2004.

39. Климко Н.Н. Микозы легких. Пособие для врачей. М., Премьер МТ; 2005.

40. Козлова Я.И., Борзова Ю.В., Васильева Н.В. и др. Возможная этиологическая роль микромицетов — контаминантов жилых и производственных помещений в патогенезе инвазивного аспергиллеза. Описание двух клинических случаев. Пробл мед микол 2006;8(1):24–8.

41. Ascioglu S., Rex J.H., De Pauw B. et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7–14.

42. Johnson L.B., Kauffman C.A. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36: 630–7.